Strategic IP Support since 1997
Recent Insights & News
Who sets the price of your IP? Why the licence decides, not the patent
The patent is rarely where the money is decided. The licence is. Three IP developments from the past week make that point, and each turns on terms settled, or left unsettled, long before anyone reached a court. In the United Kingdom, the government has published its response to its consultation on standard essential patents, the…
Who keeps the profit when AI makes the product? The trade secret test for your AI strategy
If AI collapses the cost of making your product, the question is no longer how cheaply you can make it. It is what stops a competitor making the same thing. That is a trade secret and patent question, and most AI strategies never get to it. A Bain & Company analysis puts a number on…
Who Gets to Scale It? What China’s Energy Plans Say About Your Patent Filing Strategy
There are two ways to hold a position in a technology. You can own the technology. Or you can own what it takes to build and install the technology at volume. They are not the same asset, and only one of them is scarce. China spent August publishing the second kind. A five-year plan for…
Does your AI strategy move you, or just add a feature? The IP test for platform partnerships
Adding AI to a product is not a strategy. Moving to where the value is going is. And every real move changes what your company controls, which makes it an IP strategy decision before it is a technology one. An article in I by IMD puts this well. It maps AI strategy on two axes:…
Owning the Mechanism Is Not a Position: What a Failed Trial Says About Patent Strategy
A patent protects a mechanism. It does not protect a share of the benefit. Those are different things, and the gap between them is where a great deal of intellectual property value quietly disappears. Cardiology supplied the evidence this month. AstraZeneca and Ionis ran a 1,432-patient Phase 3 trial of a transthyretin silencer in ATTR-CM,…
